Policy | February 24, 2026
India shifts focus from 'Pharmacy of the World' to 'Global Innovation Hub', says Health Minister Nadda
Nadda underlined that India’s policy framework is aligned with this transformation
Nadda underlined that India’s policy framework is aligned with this transformation
The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
Developed using STEERLife’s proprietary FragMelt continuous processing platform, the approval marks a major breakthrough in pharmaceutical manufacturing
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
Subscribe To Our Newsletter & Stay Updated
